Stock Scorecard



Stock Summary for Ideaya Biosciences Inc (IDYA) - $33.32 as of 4/1/2026 2:46:13 PM EST

Total Score

9 out of 30

Safety Score

35 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for IDYA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for IDYA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for IDYA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for IDYA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for IDYA (35 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for IDYA

A Look At IDEAYA Biosciences (IDYA) Valuation After Early IDE849 And IDE161 Combination Trial Activity 4/1/2026 9:40:00 PM
Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA) 3/31/2026 2:38:00 PM
37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL 3/31/2026 11:38:00 AM
IDEAYA moves new cancer drug combo into patients after early lung tumor responses 3/30/2026 9:59:00 AM
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma 3/30/2026 9:59:00 AM
Is It Too Late To Consider IDEAYA Biosciences (IDYA) After Its Strong Multi Year Run 3/29/2026 11:09:00 PM
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 3/27/2026 11:40:00 PM
Vanguard disaggregates holdings; affiliates to report separately (IDYA) 3/27/2026 1:40:00 PM
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 3/27/2026 10:10:00 AM
Two new IDEAYA hires receive options for 49,000 shares total 3/27/2026 9:40:00 AM

Financial Details for IDYA

Company Overview

Ticker IDYA
Company Name Ideaya Biosciences Inc
Country N/A
Description IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/5/2026

Stock Price History

Last Day Price 33.32
Price 4 Years Ago 18.17
Last Day Price Updated 4/1/2026 2:46:13 PM EST
Last Day Volume 813,476
Average Daily Volume 936,420
52-Week High 39.28
52-Week Low 13.45
Last Price to 52 Week Low 147.73%

Valuation Measures

Trailing PE N/A
Industry PE 23.00
Sector PE 113.00
5-Year Average PE -16.46
Free Cash Flow Ratio 26.03
Industry Free Cash Flow Ratio 12.92
Sector Free Cash Flow Ratio 22.21
Current Ratio Most Recent Quarter 11.34
Total Cash Per Share 1.28
Book Value Per Share Most Recent Quarter 11.65
Price to Book Ratio 2.81
Industry Price to Book Ratio 85.58
Sector Price to Book Ratio 26.97
Price to Sales Ratio Twelve Trailing Months 12.23
Industry Price to Sales Ratio Twelve Trailing Months 16.94
Sector Price to Sales Ratio Twelve Trailing Months 6.64
Analyst Buy Ratings 13
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 87,814,000
Market Capitalization 2,925,962,480
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 58.58%
Reported EPS 12 Trailing Months -1.28
Reported EPS Past Year -1.31
Reported EPS Prior Year -3.30
Net Income Twelve Trailing Months -113,698,000
Net Income Past Year -113,698,000
Net Income Prior Year -274,477,000
Quarterly Revenue Growth YOY 55.40%
5-Year Revenue Growth 62.11%
Operating Margin Twelve Trailing Months -870.00%

Balance Sheet

Total Cash Most Recent Quarter 112,825,000
Total Cash Past Year 112,825,000
Total Cash Prior Year 84,378,000
Net Cash Position Most Recent Quarter 112,825,000
Net Cash Position Past Year 112,825,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,022,934,000
Total Stockholder Equity Prior Year 1,059,147,000
Total Stockholder Equity Most Recent Quarter 1,022,934,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -73,466,000
Free Cash Flow Per Share Twelve Trailing Months -0.84
Free Cash Flow Past Year -73,466,000
Free Cash Flow Prior Year -251,441,000

Options

Put/Call Ratio 0.05
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.55
MACD Signal -0.25
20-Day Bollinger Lower Band 29.80
20-Day Bollinger Middle Band 33.49
20-Day Bollinger Upper Band 37.18
Beta 0.03
RSI 40.07
50-Day SMA 27.67
150-Day SMA 30.11
200-Day SMA 0.00

System

Modified 4/2/2026 1:35:56 AM EST